Encompassing view of spatial and single-cell RNA sequencing renews the role of the microvasculature in human atherosclerosis
- PMID: 39715784
- DOI: 10.1038/s44161-024-00582-1
Encompassing view of spatial and single-cell RNA sequencing renews the role of the microvasculature in human atherosclerosis
Abstract
Atherosclerosis is a pervasive contributor to ischemic heart disease and stroke. Despite the advance of lipid-lowering therapies and anti-hypertensive agents, the residual risk of an atherosclerotic event remains high, and developing therapeutic strategies has proven challenging. This is due to the complexity of atherosclerosis with a spatial interplay of multiple cell types within the vascular wall. In this study, we generated an integrative high-resolution map of human atherosclerotic plaques combining single-cell RNA sequencing from multiple studies and spatial transcriptomics data from 12 human specimens with different stages of atherosclerosis. Here we show cell-type-specific and atherosclerosis-specific expression changes and spatially constrained alterations in cell-cell communication. We highlight the possible recruitment of lymphocytes via ACKR1 endothelial cells of the vasa vasorum, the migration of vascular smooth muscle cells toward the lumen by transforming into fibromyocytes and cell-cell communication in the plaque region, indicating an intricate cellular interplay within the adventitia and the subendothelial space in human atherosclerosis.
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: M.N., H.H., C.P., M.B., S.B. and V.D. are employed by Novo Nordisk A/S, which generated the spatial transcriptomics data. They hold minor stock portions as part of an employee offering program. S.H. is a co-founder and shareholder of Sequantrix GmbH and has research funding from AskBio. R.K. is a founder, shareholder and board member of Sequantrix GmbH; is a member of the scientific advisory board of Hybridize Therapeutics; has received honoraria for advisory boards and talks from Bayer, Chugai, Pfizer, Roche, Genentech, Eli Lilly and GlaxoSmithKline; and has research funding from Travere Therapeutics, Galapagos, Novo Nordisk and AskBio. All other authors indicated that no competing interests exist.
References
-
- Kaptoge, S. et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob. Health 7, e1332–e1345 (2019).
-
- Libby, P. The changing landscape of atherosclerosis. Nature 592, 524–533 (2021). - PubMed
-
- Pasterkamp, G., den Ruijter, H. M. & Giannarelli, C. False utopia of one unifying description of the vulnerable atherosclerotic plaque: a call for recalibration that appreciates the diversity of mechanisms leading to atherosclerotic disease. Arterioscler. Thromb. Vasc. Biol. 42, e86–e95 (2022). - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical